1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Bacillus Anthracis Infections - Pipeline Review, H1 2014

Bacillus Anthracis Infections - Pipeline Review, H1 2014

  • May 2014
  • -
  • Global Markets Direct
  • -
  • 48 pages

Bacillus Anthracis Infections - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Bacillus Anthracis Infections - Pipeline Review, H1 2014’, provides an overview of the Bacillus Anthracis Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bacillus Anthracis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacillus Anthracis Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacillus Anthracis Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bacillus Anthracis Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bacillus Anthracis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bacillus Anthracis Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bacillus Anthracis Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bacillus Anthracis Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Bacillus Anthracis Infections - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bacillus Anthracis Infections Overview 6
Therapeutics Development 7
Pipeline Products for Bacillus Anthracis Infections - Overview 7
Pipeline Products for Bacillus Anthracis Infections - Comparative Analysis 8
Bacillus Anthracis Infections - Therapeutics under Development by Companies 9
Bacillus Anthracis Infections - Therapeutics under Investigation by Universities/Institutes 11
Bacillus Anthracis Infections - Pipeline Products Glance 12
Early Stage Products 12
Bacillus Anthracis Infections - Products under Development by Companies 13
Bacillus Anthracis Infections - Products under Investigation by Universities/Institutes 14
Bacillus Anthracis Infections - Companies Involved in Therapeutics Development 15
Aphios Corporation 15
Evolva SA 16
Microbiotix, Inc. 17
Cellceutix Corporation 18
ContraFect Corporation 19
Bacillus Anthracis Infections - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 28
EV-009 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Marinus - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
EV-035 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
PMX-225 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
PMX-0196 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
PMX-0243 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
PMX-0231 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Epimerox - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Antibiotic Compounds - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
TAA/ecdCD40L - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Small Molecule to Inhibit Enoyl-Reductase for Bacillus Anthracis and Francisella Tularensis Infections - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Small Molecule To Inhibit DNA Helicase For Infectious Diseases - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Gamma AApeptides - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
CF-306 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Bacillus Anthracis Infections - Recent Pipeline Updates 45
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables

Number of Products under Development for Bacillus Anthracis Infections, H1 2014 7
Number of Products under Development for Bacillus Anthracis Infections - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Bacillus Anthracis Infections - Pipeline by Aphios Corporation, H1 2014 15
Bacillus Anthracis Infections - Pipeline by Evolva SA, H1 2014 16
Bacillus Anthracis Infections - Pipeline by Microbiotix, Inc., H1 2014 17
Bacillus Anthracis Infections - Pipeline by Cellceutix Corporation, H1 2014 18
Bacillus Anthracis Infections - Pipeline by ContraFect Corporation, H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Bacillus Anthracis Infections Therapeutics - Recent Pipeline Updates, H1 2014 45

List of Figures

Number of Products under Development for Bacillus Anthracis Infections, H1 2014 7
Number of Products under Development for Bacillus Anthracis Infections - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy
Anti-Infective

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.